{"product_id":"procapsgroup-pestle-analysis","title":"Procaps Group PESTLE Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMake Smarter Strategic Decisions with a Complete PESTEL View\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eGain a strategic advantage with our PESTLE Analysis of Procaps Group—uncover how political shifts, economic trends, regulatory changes, social dynamics, technological advances, and environmental pressures shape the company's outlook; buy the full report to get actionable insights, editable charts, and ready-to-use intelligence for investment, strategy, or competitive analysis.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eolitical factors\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegional Political Stability in Latin America\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePolitical shifts in Colombia, Brazil and Mexico—where Procaps generates an estimated 45% of regional revenue—reshape regulatory rules for manufacturing, pricing and importation, with Colombia’s 2024 health reform and Brazil’s 2023+ procurement policy revisions already affecting market access. By end-2025 Procaps must adapt to divergent stances on privatization and public drug procurement as governments pursue cost containment—Mexico’s federal purchases totaled about $14.5B in medicines in 2024. Regional stability is critical to secure supply chains and long-term public contracts that represent a sizable share of institutional sales.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eUnited States Trade and Regulatory Policy\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAs Procaps expands in the US, exposure to US trade policy and pharmaceutical import rules grows: US imports of pharmaceuticals reached $179.3bn in 2023, so tariff shifts or new trade agreements could raise softgel entry costs materially.\u003c\/p\u003e\n\u003cp\u003eRegulatory changes under different administrations can alter compliance expenses; aligning with US FDA cGMP and 483 trends (FDA issued ~4,300 inspectional Observations in 2024) is essential to avoid market disruptions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGovernment Healthcare Spending and Subsidies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cpmany of procaps group key markets depend on government-funded healthcare and drug subsidies with public spending accounting for over pharmaceutical consumption in several latin american countries as\u003e\u003cppolitical shifts that cut or boost healthcare budgets reduced pharma spending growth to in while colombia increased health transfers by influence procaps prescription volumes for generics and branded lines.\u003e\u003cpprocaps monitors fiscal policy closely using country-level budget forecasts and procurement tenders to model demand adjust manufacturing inventory across its contract specialty pharma segments.\u003e\n\u003c\/pprocaps\u003e\u003c\/ppolitical\u003e\u003c\/pmany\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDrug Pricing Legislation and Controls\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePolitical pressure to lower medicine costs has led countries like Colombia and Mexico to enact stricter price controls; Latin American reference pricing and procurement reforms cut ARV and vaccine prices by up to 30%–50% in recent tenders (2023–2025), squeezing margins for firms such as Procaps whose 2024 gross margin was around 28%.\u003c\/p\u003e\n\u003cp\u003eThese laws push companies toward high-volume generics or specialized niche drugs with higher margins; Procaps may need repricing, cost optimization, and portfolio shift to protect EBITDA, which fell 5% YoY in 2024.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePrice caps and tender-driven cuts: up to 50% reduction in regional tenders (2023–25)\u003c\/li\u003e\n\u003cli\u003eProcaps 2024 gross margin ≈ 28%; EBITDA down ~5% YoY\u003c\/li\u003e\n\u003cli\u003eStrategic responses: shift to high-volume generics, niche specialty products, cost optimization\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGeopolitical Supply Chain Security\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eGlobal geopolitical tensions have driven a 22% increase (2022–2024) in Western firms’ nearshoring budgets, boosting demand for regional manufacturers; Procaps can leverage this by expanding capacity in Latin America to capture diverted volumes from Asia.\u003c\/p\u003e\n\u003cp\u003ePolitical incentives—tax breaks and infrastructure grants across Mexico and Colombia totaling over $3.5B in 2023—position Procaps as a strategic partner for clients seeking supply-chain diversification.\u003c\/p\u003e\n\u003cp\u003eMaintaining strong diplomatic and commercial ties within the Pan-American corridor is critical: 60% of Procaps’ API and excipient imports could be regionalized to reduce lead times and tariff exposure.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eNearshoring budget growth +22% (2022–2024)\u003c\/li\u003e\n\u003cli\u003e$3.5B regional incentives (2023)\u003c\/li\u003e\n\u003cli\u003ePotential to regionalize 60% of inputs\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory headwinds trim margins (-5% EBITDA) as nearshoring and $3.5B incentives offer relief\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePolitical reforms in Colombia, Brazil and Mexico (45% regional revenue) plus US trade rules and FDA inspections (≈4,300 observations in 2024) raise compliance and tender pressures; public procurement ($14.5B Mexico 2024) and price caps cut margins (gross margin ≈28%, EBITDA -5% YoY 2024); nearshoring (+22% 2022–24) and $3.5B incentives offer offset opportunities.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eRegional revenue exposure\u003c\/td\u003e\n\u003ctd\u003e≈45%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMexico public purchases 2024\u003c\/td\u003e\n\u003ctd\u003e$14.5B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFDA observations 2024\u003c\/td\u003e\n\u003ctd\u003e≈4,300\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eProcaps gross margin 2024\u003c\/td\u003e\n\u003ctd\u003e≈28%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEBITDA YoY 2024\u003c\/td\u003e\n\u003ctd\u003e-5%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNearshoring growth 2022–24\u003c\/td\u003e\n\u003ctd\u003e+22%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRegional incentives 2023\u003c\/td\u003e\n\u003ctd\u003e$3.5B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eExplores how Political, Economic, Social, Technological, Environmental, and Legal forces uniquely impact Procaps Group, using region- and industry-specific data to identify risks and opportunities for strategy and investment decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eCondensed Procaps Group PESTLE insights for quick meeting use, visually grouped by category to streamline risk discussions and ready to drop into presentations or strategy packs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eE\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003economic factors\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCurrency Exchange Rate Volatility\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eProcaps operates across multiple jurisdictions and is exposed to USD\/COP volatility; the Colombian peso fell about 6.5% vs the USD in 2023 and averaged ~4.8% annual FX volatility 2021–2024, raising imported API costs and input inflation pressures.\u003c\/p\u003e\n\u003cp\u003eLarge devaluations compress local-margin pharmaceuticals and reduce USD-translated earnings for international investors—Procaps reported ~35% of 2024 revenue from Colombia, amplifying translation risk.\u003c\/p\u003e\n\u003cp\u003eHedging via forwards and FX options and geographic revenue diversification (increasing exports and Latin American sales mix) are critical—regional diversification reduced reported FX impact by an estimated 40% in 2024 risk disclosures.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInflationary Pressures on Operational Costs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBy late 2025, persistent inflation in labor, energy and logistics has raised Procaps Group’s input costs by an estimated 8–12% year-on-year, pressuring gross margins across its manufacturing sites.\u003c\/p\u003e\n\u003cp\u003eSpecialized chemical inputs and packaging materials surged 10–18% in 2024–25, forcing Procaps to deploy rigorous cost-optimization and yield-improvement programs to protect EBITDA.\u003c\/p\u003e\n\u003cp\u003eAbility to pass costs varies by market: in commodity generics margin squeeze is acute, while branded\/export segments and institutional tenders—about 35% of sales—offer greater pricing power.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInterest Rate Environment and Debt Servicing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eThe current rising-rate cycle, with Colombia's policy rate at 13.25% in 2024, raises Procaps Group's cost of capital and can constrain financing for acquisitions or plant expansions. High rates elevate debt-servicing pressure, especially after Procaps' 2023 restructuring and recent capex; analysts watch net debt\/EBITDA—reported near 3.2x in 2024—for signs of strain. Central bank moves will directly affect refinancing costs and leverage-driven credit metrics.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGrowth of the Nutraceutical Market\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eEconomic development and rising disposable incomes in emerging markets—Latin America household real income growth ~3.5% in 2024—have driven nutraceutical demand, with global market size reaching $477B in 2023 and projected CAGR ~8.5% through 2028.\u003c\/p\u003e\n\u003cp\u003eHigher margins and typically simpler regulatory pathways vs. prescription drugs boost profitability; nutraceutical gross margins often exceed 40% for finished-dose forms.\u003c\/p\u003e\n\u003cp\u003eProcaps leverages softgel manufacturing scale—over 1.2 billion softgels produced in 2024—to capture growing consumer healthcare spend and expand market share.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eGlobal nutraceutical market $477B (2023), CAGR ~8.5% to 2028\u003c\/li\u003e\n\u003cli\u003eEmerging market income growth ~3.5% (Latin America, 2024)\u003c\/li\u003e\n\u003cli\u003eFinished-dose nutraceutical margins \u0026gt;40%\u003c\/li\u003e\n\u003cli\u003eProcaps ~1.2B softgels produced (2024)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHealthcare Infrastructure Investment\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eThe Andean region and Brazil saw GDP growth of roughly 2.5–3.5% in 2024, supporting pharmacy expansion and a 6–8% rise in clinical facility openings, increasing Procaps distribution outlets.\u003c\/p\u003e\n\u003cp\u003eNational healthcare spending in Colombia and Brazil rose to about 8.5% and 9% of GDP in 2024, respectively, boosting procurement budgets for pharmaceuticals.\u003c\/p\u003e\n\u003cp\u003eDuring downturns, consumers shift to generics; generic market share reached ~55% in Brazil 2024, pressuring branded formulations.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eGDP growth 2.5–3.5% (Andes\/Brazil, 2024)\u003c\/li\u003e\n\u003cli\u003eClinical facility openings +6–8% (2024)\u003c\/li\u003e\n\u003cli\u003eHealthcare spending ~8.5% (Colombia), 9% (Brazil) of GDP (2024)\u003c\/li\u003e\n\u003cli\u003eGeneric market share ~55% (Brazil, 2024)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCurrency shock and rising input costs squeeze margins as nutraceutical demand grows\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eUSD\/COP volatility (≈4.8% annual 2021–24) and 2024 COP -6.5% hit imported API costs; input inflation +8–12% y\/y (2025) and material rises 10–18% compressed margins. Colombia sales ~35% (2024) raise translation risk; net debt\/EBITDA ~3.2x (2024) sensitive to 13.25% policy rate. Nutraceutical tailwinds: $477B market (2023), CAGR ~8.5% to 2028; 1.2B softgels produced (2024).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eUSD\/COP vol\u003c\/td\u003e\n\u003ctd\u003e~4.8%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCOP change 2023\u003c\/td\u003e\n\u003ctd\u003e-6.5%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInput cost rise 2025\u003c\/td\u003e\n\u003ctd\u003e8–12%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet debt\/EBITDA 2024\u003c\/td\u003e\n\u003ctd\u003e~3.2x\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eColombia revenue\u003c\/td\u003e\n\u003ctd\u003e~35%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNutraceutical market\u003c\/td\u003e\n\u003ctd\u003e$477B (2023)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSoftgels 2024\u003c\/td\u003e\n\u003ctd\u003e1.2B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eFull Version Awaits\u003c\/span\u003e\u003cbr\u003eProcaps Group PESTLE Analysis\u003c\/h2\u003e\n\u003cp\u003eThe preview shown here is the exact Procaps Group PESTLE Analysis you’ll receive after purchase—fully formatted, professionally structured, and ready to use for strategic and investment decision-making.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56751978250617,"sku":"procapsgroup-pestle-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/procapsgroup-pestle-analysis.png?v=1772236655","url":"https:\/\/growthsharematrix.com\/products\/procapsgroup-pestle-analysis","provider":"Growth Share Matrix","version":"1.0","type":"link"}